Evidence map›Paper›PMID 42503823›Full record

ArticleJournal of medicinal chemistry2026

Synthesis, Modeling, and Biological Properties of Fluoroprostacyclin Analogues: Potent Agonists for Prostanoid Receptors.

Changcheng Jing, Isabel Perez-Powell, Hannah Baars, Shahida Mallah, Justin S Trory, Robin A Corey, Stuart J Mundell, Xin Xu, Jay Tromans, Samantha F Moore and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Changcheng JingSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Isabel Perez-PowellSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Hannah BaarsSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Shahida MallahBristol Medical School, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Justin S TroryBristol Medical School, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Robin A CoreySchool of Psychology & Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.ORCID 0000-0003-1820-7993
Stuart J MundellBristol Medical School, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Xin XuSchool of Psychology & Neuroscience, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Jay TromansSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Samantha F MooreBristol Medical School, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Christopher J ArthurSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Ingeborg HersBristol Medical School, University of Bristol, University Walk, Biomedical Sciences Building, BristolBS8 1TD, U.K.
Varinder K AggarwalSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.ORCID 0000-0003-0344-6430

Funding

Biotechnology and Biological Sciences Research Council (BBSRC) BB/X017176/1Deutsche Forschungsgemeinschaft NAEngineering and Physical Sciences Research Council (EPSRC) EP/G036764/1Engineering and Physical Sciences Research Council (EPSRC) EP/M012530/1
6 · The paper itself

Abstract

Prostacyclin (PGI2, epoprostenol) and its more stable analogues iloprost and cicaprost are used in the treatment of pulmonary arterial hypertension (PAH) and other related diseases. Currently, PGI2 therapy is the most effective treatment for PAH, but is administered intravenously due to its instability under physiological conditions. We considered creating more chemically stable hybrids of PGI2 by merging essential features of iloprost/cicaprost with a more stable C-7 fluorinated PGI2, which maintained the cyclic enol ether. The synthesis employed our key bicyclic enal and furnished the required PGI2 analogues in just 7-8 steps, providing the most expedient route to this class of molecules. This led to the discovery of compound 9, a picomolar-potent, IP receptor-selective, and chemically stable PGI2 analogue that combined the ω-side chain of cicaprost with the C-7 difluorinated enol ether of PGI2. This compound provides the most potent PGI2 analogue tested to date.

Indexed as

EpoprostenolReceptors, ProstaglandinAnimalsBioisosterismHalogenationHumansIloprostModels, MolecularStructure-Activity RelationshipcicaprostEpoprostenolIloprostReceptors, Prostaglandin

Identifiers

PMID42503823
PMCPMC13492276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.